Search Results - "T. A. Deeva"

  • Showing 1 - 12 results of 12
Refine Results
  1. 1

    Evaluation of endothelial function and estimation of the degree of apoptosis in patients with metabolic syndrome and non-alcoholic fatty liver disease by Drapkina, O M, Deeva, T A, Ivashkin, V T

    Published in Terapevtic̆eskii arhiv (01-01-2015)
    “…To evaluate endothelial function (EF) and to estimate the level of a serum apoptosis marker (caspase-8) in patients with metabolic syndrome (MS) and in those…”
    Get full text
    Journal Article
  2. 2

    Current approaches to diagnosing and treating nonalcoholic fatty liver disease by Drapkina, O M, Deeva, T A, Volkova, N P, Ivashkin, V T

    Published in Terapevtic̆eskii arhiv (01-01-2014)
    “…Nonalcoholic fatty liver disease (NAFLD) is associated with major cardiovascular risk factors, such as type 2 diabetes mellitus, obesity, dyslipidemia,…”
    Get full text
    Journal Article
  3. 3

    Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation by Raikhelson, K. L., Maevskaya, M. V., Zharkova, M. S., Grechishnikova, V. R., Okovityi, S. V., Deeva, T. A., Marchenko, N. V., Prashnova, M. К., Ivashkin, V. T.

    “…Aim: localization of the new nomenclature of steatotic liver disease in Russian clinical practice. Key points. In 2023, international consensus decided to…”
    Get full text
    Journal Article
  4. 4

    PROGNOSTIC SIGNIFICANCE OF GALECTIN-3 LEVEL ASSESSMENT IN METABOLIC SYNDROME PATIENTS WITH HEART FAILURE by Drapkina, O. M., Shepel, R. N., Deeva, T. A.

    “…Aim. To assess the level of galectin-3 in blood serum of metabolic syndrome patients (MS), with heart failure (CHF).Material and methods. Totally, 43 patients…”
    Get full text
    Journal Article
  5. 5

    PROGNOSTIC SIGNIFICANCE OF GALECTIN-3 MEASUREMENT IN PATIENTS WITH METABOLIC SYNDROME AND NON-ALCOHOLIC FATTY LIVER DISEASE by Drapkina, O. M., Deeva, T. A.

    “…Aim. To assess the levels of serum fibrosis marker (galectin-3) in patients with metabolic syndrome (MS) and non-alcoholic fatty liver disease (NAFLD)Material…”
    Get full text
    Journal Article
  6. 6

    GALECTIN-3 — BIOMARKER OF FIBROSIS IN PATIENTS WITH METABOLIC SYNDROME by Drapkina, O. M., Deeva, T. A.

    Published in Rossiĭskiĭ kardiologicheskiĭ zhurnal (25-11-2015)
    “…Recent decades there was a growing amount of people with obesity, hence the amount of the associated pathologies such as arterial hypertension, heart failure,…”
    Get full text
    Journal Article
  7. 7

    EVALUATION OF LEPTIN SERUM LEVELS IN PATIENTS WITH METABOLIC SYNDROME AND LEFT VENTRICULAR MYOCARDIAL HYPERTROPHY by Drapkina, O. M., Shepel, R. N., Deeva, T. A.

    “…Aim. To study serum level of leptin in patients with the metabolic syndrome (MS), including in patients with MS in combination with left ventricular…”
    Get full text
    Journal Article
  8. 8

    PLASMA LEPTIN LEVELS IN METABOLIC SYNDROME PATIENTS WITH ISCHEMIC HEART DISEASE by Drapkina, O. M., Shepel, R. N., Deeva, T. A.

    “…Aim. To assess leptin level in blood serum of patients with metabolic syndrome (MS), including comorbidity with ischemic heart disease (IHD), to reveal…”
    Get full text
    Journal Article
  9. 9

    Epicardial fat as a new early marker of cardiovascular disease in patients with non-alcoholic fatty liver disease by O. M. Drapkina, O. N. Korneeva, T. A. Deeva

    Published in Sechenovskiĭ vestnik (01-12-2022)
    “…Excess visceral obesity is considered the hallmark of the metabolic syndrome (MS) and non-alcoholic fatty liver disease (NAFLD), which in the modern view is…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12